For three decades, Parent Project Muscular Dystrophy (PPMD) has been committed to exploring and supporting every single therapeutic possibility. We take a cutting-edge approach to accelerate finding treatments that will end Duchenne for every single person impacted by the disease.
The therapeutic pipeline of potential treatments for Duchenne has never been so full of promise. And it’s never been more important to ensure that the path to progress is clear, so that safe and effective therapies can reach the people who need them quickly and affordably.
In this section, PPMD outlines our ambitious research strategy, takes a deeper dive into the numerous therapeutic approaches being explored, helps you and your family navigate the complex world of clinical trials, and introduces you to what’s next in Duchenne research.
The Drug Development Pipeline is full of potential treatments that are being tested. These include therapeutic approaches that restore or replace dystrophin and those that treat Duchenne symptoms (such as those that protect muscles by reducing fibrosis and inflammation). The goal? To test combinations of these therapies to create the best “cocktail” for each patient.
Click on any drug in our interactive pipeline to learn more about therapies in development for Duchenne.
Learn more
